1,117 reports of this reaction
2.0% of all LAMIVUDINE reports
#10 most reported adverse reaction
ANAEMIA is the #10 most commonly reported adverse reaction for LAMIVUDINE, manufactured by ViiV Healthcare Company. There are 1,117 FDA adverse event reports linking LAMIVUDINE to ANAEMIA. This represents approximately 2.0% of all 57,073 adverse event reports for this drug.
Patients taking LAMIVUDINE who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for LAMIVUDINE, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for LAMIVUDINE:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 1,117 FDA reports for LAMIVUDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 2.0% of all adverse event reports for LAMIVUDINE, making it a notable side effect.
If you experience anaemia while taking LAMIVUDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.